Avantor Inc
$ 9.05
0.44%
27 Feb - close price
- Market Cap 6,172,606,000 USD
- Current Price $ 9.05
- High / Low $ 9.06 / 8.78
- Stock P/E N/A
- Book Value 8.24
- EPS -0.78
- Next Earning Report 2026-04-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.09 %
- 52 Week High 18.02
- 52 Week Low 8.78
About
Avantor, Inc. provides products and services to clients in the biopharmaceutical, healthcare, education and government, advanced technologies and applied materials industries in America, Europe, Asia, the Middle East and Africa. The company is headquartered in Radnor, Pennsylvania.
Analyst Target Price
$10.89
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-10-31 | 2025-08-01 | 2025-04-25 | 2025-02-07 | 2024-10-25 | 2024-07-26 | 2024-04-26 | 2024-02-14 | 2023-10-27 | 2023-07-28 | 2023-04-28 |
| Reported EPS | 0.22 | 0.22 | 0.24 | 0.23 | 0.27 | 0.26 | 0.25 | 0.22 | 0.25 | 0.25 | 0.28 | 0.29 |
| Estimated EPS | 0.2168 | 0.22 | 0.25 | 0.23 | 0.26 | 0.25 | 0.23 | 0.2 | 0.22 | 0.26 | 0.29 | 0.28 |
| Surprise | 0.0032 | 0 | -0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | -0.01 | -0.01 | 0.01 |
| Surprise Percentage | 1.476% | 0% | -4% | 0% | 3.8462% | 4% | 8.6957% | 10% | 13.6364% | -3.8462% | -3.4483% | 3.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-24 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.2036 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTR
2026-02-27 21:51:34
Avantor (AVTR) stock has experienced recent weakness, showing negative returns across various timeframes. Despite this, the company appears undervalued, with an intrinsic discount of 44.83% and trading 21% below the average analyst price target, indicating a potential entry point for investors. The perceived undervaluation is linked to Avantor's strategic investments in specialized solutions for biologics and gene therapies, positioning it for growth in higher-margin segments.
2026-02-27 14:45:00
UBS, Jefferies, and BofA Securities have all recently cut their price targets on Avantor, Inc. (NYSE: AVTR) due to disappointing fiscal 2026 guidance and limited visibility into a potential recovery. Despite the company taking some "encouraging" steps, analysts noted that the outlook was below expectations. Avantor is a key life science tools provider, but some investment firms suggest that certain AI stocks offer greater promise.
2026-02-27 09:52:46
Close Asset Management Ltd significantly reduced its stake in Avantor, Inc. by selling 4,624,400 shares, now holding only 14,000 shares. Despite this, institutional ownership remains high at 95.08%, with other major firms like Greenhaven Associates and Dodge & Cox either
2026-02-26 12:51:34
This article reports on an insider trading activity for Avantor, Inc. (AVTR) as detailed in a Form 4 SEC filing. Steven W. Eck, SVP & Chief Accounting Officer, disposed of shares to cover tax withholding obligations in connection with RSU vesting on February 23 and 24, 2026. After these transactions, Eck beneficially owned 99,333 common shares.
2026-02-26 11:52:47
Avantor, Inc. has reached a new 52-week low of USD 8.83, marking a challenging year with a 62.12% stock price decline. The company faces profitability issues, including low returns on equity and capital employed, and significant decreases in net profit and operating profit margin. These financial metrics suggest a need for strategic reevaluation amidst difficult market conditions.
2026-02-25 20:52:46
Avantor (AVTR) has seen a significant 48.1% decline in its share price over the past year, prompting a reevaluation by investors. Despite this drop, Simply Wall St's valuation model suggests the stock is currently undervalued, with a Discounted Cash Flow (DCF) analysis indicating a 43.9% discount and a Price-to-Sales (P/S) ratio of 0.95x compared to a fair ratio of 2.60x. The article presents both bullish and bearish narratives for Avantor, with fair value estimates ranging from US$13.04 to US$8.00 per share, based on different assumptions regarding revenue growth, industry demand, and cost pressures.
